These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35339648)

  • 1. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
    Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
    Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-specific differences in immunogenomic features of response to immune checkpoint blockade.
    Scott SC; Shao XM; Niknafs N; Balan A; Pereira G; Marrone KA; Lam VK; Murray JC; Feliciano JL; Levy BP; Ettinger DS; Hann CL; Brahmer JR; Forde PM; Karchin R; Naidoo J; Anagnostou V
    Front Oncol; 2022; 12():945798. PubMed ID: 35992816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
    Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
    Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.
    Mei J; Jiang G; Chen Y; Xu Y; Wan Y; Chen R; Liu F; Mao W; Zheng M; Xu J
    BMC Cancer; 2022 Jul; 22(1):738. PubMed ID: 35794593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
    Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
    Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer.
    Lau D; Khare S; Stein MM; Jain P; Gao Y; BenTaieb A; Rand TA; Salahudeen AA; Khan AA
    Nat Commun; 2022 Jul; 13(1):4053. PubMed ID: 35831288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
    Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
    Berner F; Bomze D; Lichtensteiger C; Walter V; Niederer R; Hasan Ali O; Wyss N; Bauer J; Freudenmann LK; Marcu A; Wolfschmitt EM; Haen S; Gross T; Abdou MT; Diem S; Knöpfli S; Sinnberg T; Hofmeister K; Cheng HW; Toma M; Klümper N; Purde MT; Pop OT; Jochum AK; Pascolo S; Joerger M; Früh M; Jochum W; Rammensee HG; Läubli H; Hölzel M; Neefjes J; Walz J; Flatz L
    Sci Immunol; 2022 Sep; 7(75):eabn9644. PubMed ID: 36054337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
    Shao XM; Bhattacharya R; Huang J; Sivakumar IKA; Tokheim C; Zheng L; Hirsch D; Kaminow B; Omdahl A; Bonsack M; Riemer AB; Velculescu VE; Anagnostou V; Pagel KA; Karchin R
    Cancer Immunol Res; 2020 Mar; 8(3):396-408. PubMed ID: 31871119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response.
    Chen S; Xie D; Li Z; Wang J; Hu Z; Zhou D
    Commun Biol; 2024 Jun; 7(1):770. PubMed ID: 38918569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.
    Di Modugno F; Di Carlo A; Spada S; Palermo B; D'Ambrosio L; D'Andrea D; Morello G; Belmonte B; Sperduti I; Balzano V; Gallo E; Melchionna R; Panetta M; Campo G; De Nicola F; Goeman F; Antoniani B; Carpano S; Frigè G; Warren S; Gallina F; Lambrechts D; Xiong J; Vincent BG; Wheeler N; Bortone DS; Cappuzzo F; Facciolo F; Tripodo C; Visca P; Nisticò P
    EBioMedicine; 2024 Mar; 101():105003. PubMed ID: 38340557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
    Chowell D; Morris LGT; Grigg CM; Weber JK; Samstein RM; Makarov V; Kuo F; Kendall SM; Requena D; Riaz N; Greenbaum B; Carroll J; Garon E; Hyman DM; Zehir A; Solit D; Berger M; Zhou R; Rizvi NA; Chan TA
    Science; 2018 Feb; 359(6375):582-587. PubMed ID: 29217585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer.
    Datar IJ; Hauc SC; Desai S; Gianino N; Henick B; Liu Y; Syrigos K; Rimm DL; Kavathas P; Ferrone S; Schalper KA
    Clin Cancer Res; 2021 May; 27(10):2837-2847. PubMed ID: 33602682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
    Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
    Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.